Sudoscan to Take Part in NEUROdiab 2025 in Bucharest
Sudoscan is pleased to announce its participation in the 35th Annual Meeting of the Diabetic Neuropathy Study Group (NEUROdiab), taking place from 11 to 14 September 2025 at the Crowne Plaza in Bucharest, Romania.
This essential gathering convenes leading clinicians and researchers specializing in diabetic neuropathy. Sudoscan is proud to contribute to this conversation through its innovative, non-invasive diagnostic technology.
About the NEUROdiab Meeting
Organized by the Diabetic Neuropathy Study Group, NEUROdiab is recognized as the foremost international scientific meeting dedicated to diabetic neuropathy. With a strong focus on early detection and disease progression, this year’s meeting will highlight how clinical tools, digital health, and artificial intelligence can support more precise and timely diagnoses.
Highlights include:
● Symposia on small and large fiber neuropathies, autonomic dysfunction, and diabetic foot complications,
● Sessions covering AI applications, biomarkers, and translational research,
● Poster and oral presentations from global contributors,
● Awards for young investigators, including the Göran Sundkvist and Angelika Bierhaus prizes.
Additionally, delegates can participate in cultural excursions such as a Bucharest Old Town walking tour, a full historical day tour, and a Sinaia & Bran (Dracula’s Castle) trip. If you want to learn more about the 2025 NEUROdiab’s program, click here.
Sudoscan: Non-Invasive, Fast, Evidence-Based
Sudoscan is a CE‑certified and FDA-cleared Class IIa medical device, now present in over 34 countries, with thousands of systems in clinical use. It applies a low‑voltage, painless current to the palms and soles to measure Electrochemical Skin Conductance (ESC) a reliable marker for small‑fiber and autonomic nerve function.
● Why it matters: Sudomotor dysfunction is often among the earliest signs of diabetic autonomic neuropathy.
● Fast & simple: Delivers results in under 3 minutes operator-independent, quantitative, and reproducible.
● Clinically proven: Supported by numerous peer‑reviewed publications demonstrating correlation with skin biopsy, QSART, and cardiovascular reflex tests.
For more studies on the efficacy of Sudoscan’s technology in diabetes management, visit our publications page.
Visit Sudoscan at NEUROdiab 2025
We invite healthcare professionals and researchers to meet the Sudoscan team at the Crowne Plaza exhibition area. Discover live demos of ESC testing, explore data-driven clinical integration, and discuss practical applications in diagnostic workflows.
For full program details, registration, and more information, please visit the official NEUROdiab 2025 website.
